[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stage-iv-nsclc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stage-iv-nsclc":15},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100567701","evaluating-a-fasting-mimicking-diet-in-combination-with-immunotherapy-in-patients-with-non-small-cell-lung-cancer-100567701",false,"NCT06671613","Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer","Evaluating the Impact of Intermittent Fasting in Combination With Checkpoint Inhibitors in Patients With Non-small Cell Lung Cancer","Stage IV NSCLC","Inclusion Criteria:\n\n* 18 years at the time of informed consent\n* Ability to provide written informed consent and HIPAA authorization.\n* Eastern cooperative group (ECOG) performance status of 0 to 2\n* Newly diagnosed histologically or cytologically confirmed stage IV Non-Small Cell Lung Cancer (NSCLC). Patients with locally advanced NSCLC that are not candidates for definitive therapy but are candidates for trial are allowed per investigator discretion.\n* BMI 19 kg\u002Fm2\n* Patients should be enrolled prior to starting standard of care immunotherapy for the treatment of stage IV NSCLC. Patients should be on PD (L)1 inhibitor alone (i.e., with PD-L1 expression 50%) in the metastatic setting. The investigators will allow single agent pembrolizumab only as the checkpoint inhibitor.\n* Patients requiring palliative radiation or definitive radiation to an oligometastatic disease prior to the initiation of single agent checkpoint inhibitors are allowed once radiation has been completed and patients have recovered from toxicities.\n\nExclusion Criteria:\n\n* Self-reported weight loss of \\> 10% in the 6 weeks prior to study entry\n* History of symptomatic hypoglycemia or uncontrolled diabetes\n* Prior therapies with inhibitors of insulin growth factor I(IGF-1) such as Linsitinib or Picropodophyllin\n* Concurrent use of somatostatin\n* Concurrent use of immunosuppressive medications including sirolimus, tacrolimus, mycophenolate mofetil, azathioprine, prednisone, dexamethasone, or cyclosporine\n* Significant food allergies which would make the subject unable to consume the food provided.\n* History or current evidence of any uncontrolled medical or psychiatric condition, therapy that may confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the participating subject as deemed by the treating investigator.\n* Pregnant or lactating females are not eligible.","ALL","18 Years",{"count":20,"type":21},66,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this study is to learn the effects of fasting on cancer cells while you get maintenance treatment.",[15,27,28,29],"NSCLC","Immunotherapy","Fasting Mimicking Diet",[31,32,33,27,34],"PD1 inhibitors","Phase 2","Open Label","Fasting","RECRUITING","2025-11-05",{"date":38,"type":39},"2025-11-10","ACTUAL",{"date":41,"type":39},"2025-10-27",{"date":43,"type":21},"2030-12-31",{"name":45,"class":46},"VA Office of Research and Development","FED",4,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":4},"100515222","evaluate-the-efficacy-and-safety-of-aspirin-in-combination-with-trametinib-and-dabrafenib-100515222","NCT05988697","Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib","An Observational Phase II Study to Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib in Advanced Non-small Cell Lung Cancer Patients With BRAF V600E Mutation","Inclusion Criteria:\n\n1. Inoperable stage IIIB-IV patients with non-small cell lung cancer;\n2. BRAF V600E mutation;\n3. Dabrafenib and Trametinib are planned for treatment, and the survival period is expected to be more than 3 months;\n4. ECOG PS 0\u002F1;\n5. The diameter of the primary lesion should be at least 1cm;\n6. Previous or current aspirin treatment was allowed\n\nExclusion Criteria:\n\n1. The patient is currently receiving other anticoagulant therapy;\n2. The patient was previously treated with systemic anti-NSCLC;\n3. The patient had other positive driver mutations, including EGFR, ALK, ROS1, MET14, RET, etc.\n4. The patient had contraindications for dalafenib or trametinib and aspirin use;\n5. Patients who refused follow-up visits;","75 Years",{"count":57,"type":21},36,"OBSERVATIONAL","The purpose of this study is to observe the safety and efficacy of Aspirin combined with Trametinib and Dalafenib in the treatment of advanced BRAF V600E mutated non-small cell lung cancer (NSCLC)",[27,61,62,63,15],"BRAF V600E Mutation","Advanced Cancer","Stage IIIB NSCLC",[27,65,66,67,68,69],"Asprin","Dabrafenib","Trametinib","PFS","BRAF V600E mutation","NOT_YET_RECRUITING","2023-10-11",{"date":73,"type":39},"2023-10-12",{"date":75,"type":21},"2023-11-01",{"date":77,"type":21},"2027-04-01",{"name":79,"class":80},"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","OTHER"]